Innate Pharma (IPHA) Net Income - Minority (2018 - 2025)

Innate Pharma (IPHA) has 8 years of Net Income - Minority data on file, last reported at $25.3 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income - Minority rose 367.63% year-over-year to $25.3 million; the trailing twelve-month figure through Dec 2025 stood at $25.3 million (up 367.63% YoY), and the FY2025 full-year result was $25.3 million, up 367.63% from the prior year.
• Net Income - Minority for Q4 2025 stood at $25.3 million, up from -$9.4 million in the prior quarter.
• Across five years, Net Income - Minority topped out at $25.3 million in Q4 2025 and bottomed at -$122.9 million in Q4 2021.
• The 5-year median for Net Income - Minority is -$55.2 million (2022), against an average of -$43.6 million.
• The widest annual swing landed in 2023, when Net Income - Minority dropped 1.08%; it then surged 367.63% in 2025.
• A 5-year view of Net Income - Minority shows it stood at -$122.9 million in 2021, then jumped by 55.05% to -$55.2 million in 2022, then retreated by 1.08% to -$55.8 million in 2023, then soared by 83.1% to -$9.4 million in 2024, then jumped by 367.63% to $25.3 million in 2025.
• The last three Net Income - Minority figures came in at $25.3 million (Q4 2025), -$9.4 million (Q4 2024), and -$55.8 million (Q4 2023), per Business Quant data.

Peer Comparison